Galmed Pharmaceuticals Ltd (GLMD)

Etorro trading 970x250

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Address: 16 Tiomkin Street, Tel Aviv, Israel, 6578317

Galmed Pharmaceuticals Ltd News and around…

Latest news about Galmed Pharmaceuticals Ltd (GLMD) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
18 May, 2022 FinancialContent

Upgrades According to William Blair, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. At ...

Galmed Pharmaceuticals: Q1 Earnings Insights
17 May, 2022 FinancialContent

Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here's what ...

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
17 May, 2022 Yahoo! Finance

TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects
17 May, 2022 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases announced today the Company's clinical development strategy will expand into new anti-fibrotic indications to maximize the potential of its lead compound, Aramchol while at the same time discontinuing the Open Label Part of the Armor Study having reached its objectives.

80 Biggest Movers From Yesterday
04 May, 2022 FinancialContent

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX ...

Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know
03 May, 2022 FinancialContent

Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from ...

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
03 May, 2022 FinancialContent

Upgrades For SVB Financial Group (NASDAQ:SIVB), Oppenheimer upgraded the previous rating of Perform to Outperform. For the first ...

66 Biggest Movers From Yesterday
03 May, 2022 FinancialContent

Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on ...

Recap: Galmed Pharmaceuticals Q4 Earnings
02 May, 2022 FinancialContent

Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q4 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what ...

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
02 May, 2022 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and twelve months ended December 31, 2021.

Earnings Scheduled For May 2, 2022
02 May, 2022 FinancialContent

Companies Reporting Before The Bell • New Gold (AMEX:NGD) is estimated to report quarterly earnings at $0.03 per share ...

Galmed Pharmaceuticals's Earnings Outlook
29 Apr, 2022 FinancialContent

Galmed Pharmaceuticals (NASDAQ:GLMD) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors ...

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
28 Apr, 2022 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today interim results from the Open-Label Part of the ARMOR study showing fibrosis improvement with Aramchol using multimodality histological assessment.

Galmed Pharmaceuticals Q4 2021 Earnings Conference Call On May 2, 2022 At 08:30 AM ET
27 Apr, 2022 FinancialContent

Galmed Pharmaceuticals (NASDAQ:GLMD) will host a conference call at 08:30 AM ET on May 2, 2022, to discuss Q4 2021 earnings ...

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
26 Apr, 2022 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Monday, May 2, 2022, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss

These 10 Penny Stocks are Trending on Reddit
29 Mar, 2022 Yahoo! Finance

In this article, we take a look at the 10 penny stocks that are trending on Reddit. If you want to skip reading about how penny stocks have exploded in the past, you can go directly to These 5 Penny Stocks are Trending on Reddit. Buy Low, Sell High A penny stock, also known as […]

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
18 Mar, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

25 Stocks Moving in Friday's Pre-Market Session
18 Mar, 2022 FinancialContent

Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) ...

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
11 Jan, 2022 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota. An additional patent grant protects the low dose composition of Aramchol salt until June 8, 2036. With these latest pat

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study
10 Jan, 2022 FinancialContent

Galmed Pharmaceuticals Ltd(NASDAQ: GLMD)posted resultsof the Phase 1 trial of Amilo-5MER in healthy ...

Galmed announces positive results of Phase 1 study of Amilo-5MER
10 Jan, 2022 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a Phase 1 clinical trial of Amilo-5MER in healthy volunteers that demonstrated an excellent safety profile and tolerability.

Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement
08 Nov, 2021 FinancialContent

Galmed Pharmaceuticals Ltd(NASDAQ: GLMD) hasannounced histology and biomarkers analysis resultsfrom the Ongoing ...

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
08 Nov, 2021 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and nine months ended September 30, 2021.

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement
08 Nov, 2021 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from histology and biomarkers analyses in the ongoing Open-Label Part of the ARMOR Phase 3 study.

26 Stocks Moving in Monday's Pre-Market Session
08 Nov, 2021 FinancialContent

Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science ...

Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial
01 Nov, 2021 FinancialContent

Galmed Pharmaceuticals Ltd(NASDAQ: GLMD)announced results from the first 16 patientsin the Open-Label Part of the ...

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
01 Nov, 2021 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
11 Oct, 2021 Yahoo! Finance

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine (https://www.nature.com/articles/s41591-021-01495-3).

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
24 Aug, 2021 Yahoo! Finance

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
19 Aug, 2021 FinancialContent

Galmed Pharmaceuticals Ltd(NASDAQ: GLMD) hasannounced the data publicationfor its preclinical compound, Amilo-5MER, ...

Galmed Pharmaceuticals Ltd (GLMD) is a NASDAQ Common Stock listed in , ,

970x250